Monday, February 12, 2018

6:30 p.m.-8:15 p.m.  WELCOME AND KEYNOTE LECTURES
Legends I-IV

6:30 p.m.-6:45 p.m.  Welcome
Conference Cochairs

6:45 p.m.-7:30 p.m.  Differential regulation of inflammation in the brain and spinal cord
Joan M. Goverman, University of Washington, Seattle, WA

7:30 p.m.-8:15 p.m.  Systemic immune therapies for treating brain metastasis and their effects on the tumor microenvironment in the brain
Harriet M. Kluger, Yale University, New Haven, CT

8:30 p.m.-10:00 p.m.  OPENING RECEPTION
Legends V-VI

Tuesday, February 13, 2018

Basic Insights into Immune Mechanisms of CNS that Could Be Relevant to Unique CNS Tumor Environment

7:00 a.m.-8:00 a.m.  CONTINENTAL BREAKFAST
Encore

8:00 a.m.-10:00 a.m.  PLENARY SESSION 1: PRINCIPLES THAT GOVERN UNIQUE ASPECTS OF THE HOST IMMUNE RESPONSE WITHIN THE BRAIN
Legends I-IV
Session Chair: Glenn F. Rall, Fox Chase Cancer Center, Philadelphia, PA

8:00 a.m.-8:30 a.m.  CNS-draining lymphatics in regulation of meningeal immunity
Antoine Louveau, University of Virginia School of Medicine, Charlottesville, VA

8:30 a.m.-9:00 a.m.  Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment
Aaron Diaz, University of California San Francisco, San Francisco, CA

9:00 a.m.-9:30 a.m.  Modeling cerebral edema in immunotherapy recipients
Glenn F. Rall

9:30 a.m.-9:45 a.m.  Integrated omics analysis of temporal changes of neoantigen and tumor microenvironment in primary and recurrent gliomas*
Takahide Nejo, Department of Neurosurgery, The University of Tokyo, Tokyo, Japan

9:45 a.m.-10:00 a.m.  Contraction of T-cell richness in brain metastases of non-small cell lung cancers*
Aaron Mansfield, Mayo Clinic, Rochester, MN

*Short talk from proffered abstract
CONFERENCE PROGRAM

10:00 a.m.-10:30 a.m. BREAK Abbey Road

10:30 a.m.-12:30 p.m. PLENARY SESSION 2: CNS IMMUNOLOGY: EFFECTOR MECHANISM (THE EFFERENT ARM OF CNS IMMUNITY)
Legends I-IV
Session Chair: Robyn S. Klein, Washington University School of Medicine, St. Louis, MO

10:30 a.m.-11:00 a.m. Innate immune regulation of blood-brain barrier function
Robyn S. Klein

11:00 a.m.-11:30 a.m. Regulatory programs mediated by lectins and glycans in CNS immunopathology
Gabriel A. Rabinovich, Instituto de Biología y Medicina Experimental, CONICET, Buenos Aires, Argentina

11:30 a.m.-12:00 p.m. Microglial responses at the blood-brain barrier
Dimitrios Davalos, Cleveland Clinic Lerner Research Institute, Cleveland, OH

12:00 p.m.-12:15 p.m. Intravital imaging of CAR-T cells directed against GD2 in a preclinical immunocompetent glioblastoma model*
Surya Murty, Stanford University, Stanford, CA

12:15 p.m.-12:30 p.m. Adoptive cell therapy for high-grade gliomas using simultaneous temozolomide and intracranial MGMT-modified γδ T cells following standard post-resection chemo and radiotherapy*
Lawrence Lamb, University of Alabama at Birmingham, Birmingham, AL

12:30 p.m.-3:15 p.m. POSTER SESSION A / LUNCH
Legends V-VI / Encore

3:15 p.m.-5:45 p.m. PLENARY SESSION 3: THE CNS TUMOR MICROENVIRONMENT
Legends I-IV
Session Chair: Hideho Okada, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

3:15 p.m.-3:45 p.m. Gliomas: Big data visualization and mouse modeling
Eric C. Holland, Fred Hutchinson Cancer Research Center, Seattle, WA

3:45 p.m.-4:15 p.m. Sex-specific modifiers of brain tumor risk
Joshua B. Rubin, Washington University School of Medicine, McDonnell Genome Institute, St. Louis, MO

4:15 p.m.-4:45 p.m. Immunopathology of brain tumors: Relevance of immune infiltrates
Christel Herold-Mende, University of Heidelberg, Heidelberg, Germany

4:45 p.m.-5:15 p.m. Neoantigens and mutation-induced immunoregulatory mechanisms in gliomas
Hideho Okada

5:15 p.m.-5:30 p.m. Discrimination of response to CAR T-cell therapy using a novel response metric incorporating tumor growth kinetics in recurrent GBM patients*
Gustavo De Leon, Mayo Clinic, Phoenix, AZ

*Short talk from proffered abstract
5:30 p.m.-5:45 p.m.  Vascular niche regulates alternative macrophage activation in glioblastoma immunity*
Yi Fan, University of Pennsylvania, Philadelphia, PA

DINNER ON OWN / EVENING OFF

Wednesday, February 14, 2018
Brain Metastasis and Enhancing Immune Responses to CNS Malignancies

7:00 a.m.-8:00 a.m.  CONTINENTAL BREAKFAST
Encore

8:00 a.m.-10:00 a.m.  PLENARY SESSION 4: CNS METASTASIS
Legends I-IV
Session Chair: Patricia S. Steeg, National Cancer Institute, Bethesda, MD

8:00 a.m.-8:30 a.m.  What is the status of blood-tumor barrier and immune cells in brain met models?
Patricia S. Steeg

8:30 a.m.-9:00 a.m.  Innate immunity in parenchymal and leptomeningeal metastasis: Mechanism and therapeutic opportunities
Adrienne A. Boire, Memorial Sloan Kettering Cancer Center, New York, NY

9:00 a.m.-9:30 a.m.  The inflammatory microenvironment in brain metastases as a therapeutic target
Anna Sophie Berghoff, Medical University of Vienna, Vienna, Austria

9:30 a.m.-9:45 a.m.  Syndecan 1/IL-8 axis facilitates breast cancer brain metastasis through modulation of blood-brain barrier permeability*
Sierra Mosticone Wangensteen, Virginia Commonwealth University, Richmond, VA

9:45 a.m.-10:00 a.m.  Ligand-independent EphA2 signaling drives an amoeboid melanoma phenotype that metastasizes to the brain*
Inna Smalley, The Moffitt Cancer Center & Research Institute, Tampa, FL

10:00 a.m.-10:30 a.m.  BREAK
Abbey Road

*Short talk from proffered abstract
CONFERENCE PROGRAM

10:30 a.m.-12:30 p.m. PLENARY SESSION 5: CHECKPOINT PATHWAYS RELEVANT TO CNS
Legends I-IV
Session Chair: Robert M. Prins, David Geffen School of Medicine at UCLA, Los Angeles, CA

10:30 a.m.-11:00 a.m. Challenges in testing immunotherapies in clinical trials
Mark R. Gilbert, NCI-CCR, Bethesda, MD

11:00 a.m.-11:30 a.m. Immune checkpoint biomarkers in CNS gliomas and metastasis
Amy B. Heimberger, The University of Texas MD Anderson Cancer Center, Houston, TX

11:30 a.m.-12:00 p.m. Immune checkpoint blockade in patients with melanoma metastatic to the brain
Kim A. Margolin, City of Hope, Duarte, CA

12:00 p.m.-12:15 p.m. Influence of PD-1 antibody blockade on the tumor microenvironment in patients with recurrent glioblastoma*
Aaron Mochizuki, University of California Los Angeles, Los Angeles, CA

12:15 p.m.-12:30 p.m. The immune landscape of PD-1 expression in human glioblastoma*
Alexander Lee, University of California Los Angeles, Los Angeles, CA

12:30 p.m.-3:15 p.m. POSTER SESSION B / LUNCH
Legends V-VI / Encore

3:15 p.m.-5:30 p.m. PLENARY SESSION 6: ADOPTIVE T-CELL THERAPY FOR CNS MALIGNANCIES
Legends I-IV
Session Chair: Christine Brown, City of Hope, Duarte, CA

3:15 p.m.-3:45 p.m. Adoptively transferred T cells for primary and secondary CNS malignancies
Richard M. Sherry, National Cancer Institute, Bethesda, MD

3:45 p.m.-4:15 p.m. CAR T cell immunotherapy of brain tumors and associated neurotoxicities
Michael C. Jensen, Seattle Children’s Research Institute, Seattle, WA

4:15 p.m.-4:45 p.m. Neurotoxicity observed in CD19 CAR therapy
Hyam I. Levitsky, Juno Therapeutics, Seattle, WA (not eligible for CME credit)

4:45 p.m.-5:00 p.m. New therapeutic approach for central nervous system lymphoma by CD19 CAR T cells*
Xiuli Wang, City of Hope National Medical Center, Duarte, CA

5:00 p.m.-5:15 p.m. Cloning and characterization of T-cell receptors reactive to the mutant isocitrate dehydrogenase-1-derived neoepitope in low-grade gliomas*
Payal Watchmaker, Department of Neurological Surgery, University of California San Francisco, San Francisco, CA

5:15 p.m.-5:30 p.m. Co-stimulatory domain 41BB (CD137) improves specificity and proliferative potential of IL13Ra2-specific CAR T cells for the treatment of glioblastoma*
Renate Starr, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA

DINNER ON OWN / EVENING OFF

*Short talk from proffered abstract

IMMUNOBIOLOGY OF PRIMARY AND METASTATIC CNS CANCER
Thursday, February 15, 2018
Multimodality Approaches

7:00 a.m.-8:00 a.m.  CONTINENTAL BREAKFAST
Encore

8:00 a.m.-10:00 a.m.  PLENARY SESSION 7: VIRAL THERAPY
Legends I-IV
Session Chair: Noriyuki Kasahara, University of Miami Health System, Miami, FL

8:00 a.m.-8:30 a.m.  Oncolytic poliovirus immunotherapy
Matthias Gromeier, Duke University Medical Center, Durham, NC

8:30 a.m.-9:00 a.m.  Oncolytic adenovirus: The immune angle
Juan Fueyo, The University of Texas MD Anderson Cancer Center, Houston, TX

9:00 a.m.-9:15 a.m.  An oncolytic measles virus-sensitive group 3 medulloblastoma model in immune-
competent mice*
Sangeet Lal, University of California San Francisco, San Francisco, CA

9:15 a.m.-9:45 a.m.  Retroviral replicating vectors for tumor-targeted gene therapy and immunotherapy
of glioma
Noriyuki Kasahara

9:45 a.m.-10:00 a.m.  Immunologic activation in recurrent high-grade glioma patients with durable
complete response following treatment with Toca 511 and Toca FC*
Clark Chen, University of Minnesota, Minneapolis, MN

10:00 a.m.-10:15 a.m.  BREAK
Abbey Road

10:15 a.m.-12:15 p.m.  PLENARY SESSION 8: MULTIMODALITY IMMUNOTHERAPY APPROACHES
TARGETING CNS TUMOR MICROENVIRONMENT
Legends I-IV
Session Chair: Ignacio Melero, University of Navarra, Pamplona, Spain

10:15 a.m.-10:45 a.m.  Radiation therapy and PD-1 blockade in brain metastasis from breast cancer
Silvia C. Formenti, Weill Cornell Medical College, New York, NY

10:45 a.m.-11:15 a.m.  Targeted and immunotherapeutic approaches in brain metastases
Frank A. Winkler, German Cancer Research Center, Heidelberg, Germany

11:15 a.m.-11:45 a.m.  Novel combinations: Neoadjuvant presurgery and dendritic cell vaccine for
glioblastoma
Ignacio Melero

*Short talk from proffered abstract
CONFERENCE PROGRAM

11:45 a.m.-12:00 p.m.  
**IDO1 inhibition synergizes with radiation and PD-1 blockade to durably increase survival against advanced glioblastoma***  
Derek Wainwright, Northwestern University Feinberg School of Medicine, Chicago, IL

12:00 p.m.-12:15 p.m.  
**Noninvasive monitoring of in situ immunotherapeutic responses in glioblastoma using novel PET and MRI techniques***  
Joseph Antonios, University of California Los Angeles, Los Angeles, CA

12:15 p.m.-12:30 p.m.  
**CLOSING REMARKS**  
Legends I-IV  
Hideho Okada, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

12:30 p.m.  
**DEPARTURE**

*Short talk from proffered abstract*